FAIR VALUE - Narrative (Details)	1 Months Ended	12 Months Ended
	May 31, 2020 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Short-term contingent consideration		$ 14,500,000	$ 6,776,000
Long-term contingent consideration		23,159,000	31,776,000
Level 3 | Contingent consideration | Costs and expenses
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Changes in fair value		$ (3,914,000)	(1,500,000)
Revenue volatility
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input		0.35
Discount rate
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input		0.070
Credit spread
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input		0.052
Zyla Life Sciences
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, revenue percentage	20.00%
INDOCIN
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration liability		$ 37,500,000	38,400,000
Short-term contingent consideration		14,500,000	6,800,000
Long-term contingent consideration		23,000,000	31,600,000
INDOCIN | Zyla Life Sciences | Iroko
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent payment consideration, future royalties covenant, product net sales (over)	$ 20,000,000
CAMBIA
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration liability		$ 200,000	$ 200,000